Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

24.33 -1.17 (-4.59%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024

July 10, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

June 11, 2024

From Zai Lab Limited

Via Business Wire

Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 04, 2024

Via Benzinga

Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday ↗

June 04, 2024

Via Benzinga

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

May 22, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

May 20, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Participation in May and June Investor Conferences

May 16, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

May 14, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA

May 12, 2024

From Zai Lab Limited

Via Business Wire

Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

May 09, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 09, 2024

Via Benzinga

Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036

May 09, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END

Via FinancialNewsMedia

Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday ↗

May 09, 2024

Via Benzinga

Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗

May 09, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 09, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

May 09, 2024

Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!

Via InvestorPlace

ZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

ZLAB stock results show that Zai Lab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates

May 08, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

April 15, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Statement on Executive Management Team’s Agreement on Share Activities

April 11, 2024

From Zai Lab Limited

Via Business Wire

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

April 02, 2024

From Zai Lab Limited

Via Business Wire

One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details ↗

April 01, 2024

Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati...

Via Benzinga

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

April 01, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

March 27, 2024

From Zai Lab Limited

Via Business Wire

Shhh! 7 Small-Cap Stocks That Can Double by 2025 ↗

March 20, 2024

Small-cap stocks have been hot and these shares discussed here are likely to heat up and double over the next year.

Via InvestorPlace

Stock Disconnect Triggers Investor Exodus From CStone Pharma ↗

March 14, 2024

Key Takeaways: CEO Jason Yang has increased his CStone stake multiple times over the past 18 months to 4.79% of outstanding shares, signaling confidence in the company

Via Benzinga

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

March 13, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

March 06, 2024

From Zai Lab Limited

Via Business Wire

Zai Lab Announces Participation in March Investor Conference

March 06, 2024

From Zai Lab Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.